{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:08:11Z","timestamp":1773763691203,"version":"3.50.1"},"reference-count":10,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,27]]},"DOI":"10.1182\/blood.2022019339","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T16:40:50Z","timestamp":1691080850000},"page":"2037-2038","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Queen's gambit: response-adapted win in CAYA with cHL"],"prefix":"10.1182","volume":"141","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2235-4902","authenticated-orcid":false,"given":"Seda S.","family":"Tolu","sequence":"first","affiliation":[{"name":"1Columbia University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4117-2469","authenticated-orcid":false,"given":"Jennifer E.","family":"Amengual","sequence":"additional","affiliation":[{"name":"1Columbia University Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"17","key":"2023080316402662000_bib1","first-page":"2075","article-title":"Nivolumab and brentuximab vedotin with or without bendamustine for R\/R Hodgkin lymphoma in children, adolescents, and young adults","volume":"141","author":"Harker-Murray","year":"2023","journal-title":"Blood"},{"issue":"22","key":"2023080316402662000_bib2","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood.V128.22.1106.1106","article-title":"A\u00a0phase I study with an expansion cohort of the combination of ipilimumab and nivolumab and brentuximab vedotin in patients with relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412 arms D and E)","volume":"128","author":"Diefenbach","year":"2016","journal-title":"Blood"},{"key":"2023080316402662000_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(17)30912-9","article-title":"Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1\u20132 trial","volume":"19","author":"O'Connor","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023080316402662000_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"key":"2023080316402662000_bib5","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/bmt.2015.177","article-title":"A\u00a0prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma","volume":"50","author":"Satwani","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"2023080316402662000_bib6","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"key":"2023080316402662000_bib7","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"2023080316402662000_bib8","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1470-2045(15)70013-6","article-title":"PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study","volume":"16","author":"Moskowitz","year":"2015","journal-title":"Lancet Oncol"},{"key":"2023080316402662000_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"2023080316402662000_bib10","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma","volume":"387","author":"Castellino","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/17\/2037\/2069006\/blood_bld-2022-019339-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/141\/17\/2037\/2069006\/blood_bld-2022-019339-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T16:41:00Z","timestamp":1691080860000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/141\/17\/2037\/495428\/Queen-s-gambit-response-adapted-win-in-CAYA-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":10,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,4,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022019339","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]}}}